Fennec Pharmaceuticals
FENCFennec Pharmaceuticals is a commercial-stage specialty biotechnology company focused on preventing cisplatin-induced ototoxicity in pediatric cancer patients.
Earnings
Q3 2026 report
November 12, 2026Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Fennec Pharmaceuticals is a commercial-stage specialty biotechnology company focused on preventing cisplatin-induced ototoxicity in pediatric cancer patients. Its core value proposition is providing the first and only regulatory-approved therapy to reduce the risk of permanent hearing loss associated with platinum-based chemotherapy. The company operates as a virtual manufacturer, leveraging third-party partnerships for production and international commercialization.
Fennec holds a first-mover advantage as the provider of the only FDA and EMA-approved treatment for cisplatin-induced hearing loss in its specific pediatric indication.
FAQ
- What is Fennec Pharmaceuticals's market cap?
- Fennec Pharmaceuticals (FENC) has a market capitalization of $379.8M and trades on NASDAQ.
- Who are Fennec Pharmaceuticals's competitors?
- Fennec Pharmaceuticals's key competitors include TriSalus Life Sciences, Inc. Common Stock, NovoCure Limited Ordinary Shares, Spruce Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Fennec Pharmaceuticals partner with?
- Fennec Pharmaceuticals's notable partners include Norgine, Inpharmus, City of Hope, and others.
- What subsidiaries does Fennec Pharmaceuticals have?
- Fennec Pharmaceuticals's subsidiaries include Fennec Pharmaceuticals, Inc. (Delaware), Fennec Pharmaceuticals (EU) Limited, Oxiquant, Inc., and others.
- Where is Fennec Pharmaceuticals headquartered?
- Fennec Pharmaceuticals is headquartered in United States of America and employs approximately 29 people. It has been publicly traded since 2002.